Overview

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Keyriched-1 is a multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.

Phase:

Phase 2

Details

Lead Sponsor:

West German Study Group

Collaborators:

Amgen
Merck Sharp & Dohme Corp.
NanoString Technologies, Inc.

Treatments:

Pembrolizumab
Pertuzumab
Trastuzumab